Adoptive immunotherapy with recombinant human IL-2 (rHuIL-2) after autologous stem cell transplantation (ASCT) for high-risk neuroblastoma (HR-NB).

被引：0
|
作者：
Pession, A
Prete, A
Locatelli, F
Alvisi, P
Garaventa, A
Messina, C
Pierinelli, S
Bonetti, F
Cordero, L
Favre, C
Arrighini, A
Rondelli, R
DeBernandi, B
Paolucci, G
机构：
[1] DEPT PEDIAT,PAVIA,ITALY
[2] DEPT PEDIAT,TURIN,ITALY
[3] DEPT PEDIAT,PADUA,ITALY
[4] DEPT PEDIAT,PISA,ITALY
[5] DEPT PEDIAT,BRESCIA,ITALY
[6] DEPT PEDIAT,GENOA,ITALY
来源：
EXPERIMENTAL HEMATOLOGY | 1996年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：374 / 374
页数：1
相关论文
共 50 条
  • [31] Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: Results of SMC NB-2004 study
    Sung, K. W.
    Son, M. H.
    Lee, S. H.
    Yoo, K. H.
    Koo, H. H.
    Kim, J. Y.
    Cho, E. J.
    Lee, S. K.
    Choi, Y. S.
    Lim, D. H.
    Kim, J-S
    Kim, D. W.
    BONE MARROW TRANSPLANTATION, 2013, 48 (01) : 68 - 73
  • [32] Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: Results of SMC NB-2004 study
    K W Sung
    M H Son
    S H Lee
    K H Yoo
    H H Koo
    J Y Kim
    E J Cho
    S K Lee
    Y S Choi
    D H Lim
    J-S Kim
    D W Kim
    Bone Marrow Transplantation, 2013, 48 : 68 - 73
  • [33] Adoptive immunotherapy with donor lymphocyte infusions (DLI) and IL-2 after high-dose therapy (HDT) and autologous stem cell (ASC) rescue for relapsed/refractory multiple myeloma.
    Ballester, O
    Fang, T
    Bruno, G
    Willcox, P
    Vashi, P
    Payne, M
    Eldibany, M
    Tan, B
    BLOOD, 2000, 96 (11) : 196A - 196A
  • [34] Adoptive immunotherapy with haploidentical donor lymphocyte infusions (DLI) in the setting of high-dose therapy with autologous stem cell transplantation for high-risk multiple myeloma.
    Ballester, OF
    Raptis, A
    Jillella, A
    Hiemenz, J
    Wilcox, P
    Ballester, G
    Townsend, A
    BLOOD, 2002, 100 (11) : 408B - 408B
  • [35] Improved Long-Term Survival after Myeloablative Chemotherapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma Patients. Results of the NB97 Trial
    Simon, T.
    Hero, B.
    Ruth, V.
    Angelika, E.
    Frank, B.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S39 - S39
  • [36] Immunotherapy with rituximab/interleukin 2 (IL-2) following autologous peripheral blood stem cell transplant (ASCT) as treatment for CD20 positive now Hodgkin's lymphoma
    Holmberg, L
    Maloney, D
    Gooley, T
    Bensinger, WI
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 116 - 116
  • [37] Immunotherapy of leukemia using allogeneic cell-therapy and recombinant human IL-2 of relapse following allogeneic bone marrow transplantation
    Slavin, S
    Naparstek, E
    Nagler, A
    Kapelushnik, J
    Varadi, G
    Ackerstein, A
    Samuel, S
    Or, R
    BLOOD, 1995, 86 (10) : 2249 - 2249
  • [38] Iron Overload during Follow-up after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma
    Bae, Soo Jin
    Kang, Christine
    Sung, Ki Woong
    Chueh, Hee Won
    Son, Meong Hi
    Lee, Soo Hyun
    Yoo, Keon Hee
    Koo, Hong Hoe
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2012, 27 (04) : 363 - 369
  • [39] A phase III multicenter randomized trial comparing cyclophosphamide, thiotepa and carboplatin (stamp V) with or without IL-2 activated stem cell transplantation and parenteral IL-2 for high-risk breast cancer.
    Meehan, KR
    Ballen, K
    Boccia, R
    Ahmed, U
    Hill, JM
    Herscowitz, H
    Gehan, E
    Hayes, DF
    Lippman, ME
    BLOOD, 1999, 94 (10) : 352A - 352A
  • [40] Treatment with interleukin-2 (IL-2) and interferon (IFNalpha 2b) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse
    Vivancos, P
    Granena, A
    Sarrá, J
    Grañena, A
    BONE MARROW TRANSPLANTATION, 1999, 23 (02) : 169 - 172
12345